See more : Keynote Financial Services Limited (KEYFINSERV.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Anixa Biosciences, Inc. (ANIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anixa Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lazydays Holdings Inc (LAZYW) Income Statement Analysis – Financial Results
- Nomura Research Institute, Ltd. (NRILY) Income Statement Analysis – Financial Results
- HighTide Therapeutics Inc (2511.HK) Income Statement Analysis – Financial Results
- OKG Technology Holdings Limited (1499.HK) Income Statement Analysis – Financial Results
- Fundamental Invest Stock Pick (FUISP.CO) Income Statement Analysis – Financial Results
Anixa Biosciences, Inc. (ANIX)
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 210.00K | 2.47B | 512.50K | 0.00 | 250.00K | 1.11M | 362.50K | 300.00K | 9.26M | 3.67M | 388.85K | 940.01K | 1.00M | 730.68K | 1.06M | 2.06M | 486.85K | 508.65K | 439.79K | 494.46K | 244.22K | 5.19M | 1.69M | 1.47M | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 300.00K |
| Cost of Revenue | 161.00K | 42.00K | 385.00K | 90.16K | 166.25K | 768.41K | 104.56K | 217.42K | 3.65M | 1.99M | 316.66K | 3.87K | 34.08K | 82.31K | 65.69K | 95.59K | 160.36K | 156.45K | 719.63K | 176.11K | 175.94K | 1.87M | 697.64K | 463.63K | -300.00K | -300.00K | -300.00K | -100.00K | -100.00K | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 49.00K | 2.47B | 127.50K | -90.16K | 83.75K | 344.09K | 257.94K | 82.58K | 5.61M | 1.68M | 72.19K | 936.14K | 969.11K | 648.37K | 990.11K | 1.97M | 326.49K | 352.21K | -279.84K | 318.35K | 68.28K | 3.32M | 993.13K | 1.01M | 400.00K | 400.00K | 400.00K | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 300.00K |
| Gross Profit Ratio | 23.33% | 100.00% | 24.88% | 0.00% | 33.50% | 30.93% | 71.16% | 27.53% | 60.58% | 45.79% | 18.57% | 99.59% | 96.60% | 88.74% | 93.78% | 95.37% | 67.06% | 69.24% | -63.63% | 64.38% | 27.96% | 63.93% | 58.74% | 68.50% | 400.00% | 400.00% | 400.00% | 200.00% | 200.00% | 200.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 4.77M | 6.70M | 6.19M | 4.38M | 5.47M | 6.81M | 1.60M | 1.56M | 711.39K | 1.19M | 0.00 | 2.21M | 3.12M | 3.01M | 4.12M | 4.13M | 3.40M | 4.61M | 2.27M | 2.16M | 1.81M | 1.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.90M | 2.40M | 2.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.29M | 7.17M | 7.07M | 5.60M | 5.66M | 6.91M | 4.41M | 2.71M | 5.51M | 6.41M | 7.99M | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.29M | 7.17M | 7.07M | 5.60M | 5.66M | 6.91M | 4.41M | 2.71M | 5.51M | 6.41M | 7.99M | 2.86M | 2.87M | 2.89M | 4.19M | 3.83M | 2.41M | 3.37M | 1.92M | 1.52M | 1.38M | 2.18M | 4.60M | 5.83M | 8.30M | 7.20M | 6.40M | 2.20M | 1.00M | 1.00M | 2.90M | 2.00M | 1.50M | 1.40M | 1.20M | 1.30M | 1.30M | 1.90M | 2.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 418.75K | 0.00 | -13.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.06M | 13.88M | 13.26M | 9.98M | 11.56M | 14.05M | 6.33M | 4.59M | 6.55M | 6.72M | 7.99M | 5.07M | 6.00M | 5.90M | 8.31M | 7.96M | 5.53M | 7.98M | 4.19M | 3.68M | 3.19M | 6.62M | 4.60M | 6.09M | 8.60M | 7.50M | 6.70M | 6.20M | 3.50M | 3.80M | 2.90M | 2.00M | 1.50M | 1.50M | 1.30M | 1.40M | 1.40M | 1.90M | 2.00M |
| Cost & Expenses | 11.22M | 13.88M | 13.65M | 9.98M | 11.72M | 14.82M | 6.44M | 4.81M | 10.20M | 8.71M | 8.31M | 5.07M | 6.03M | 5.98M | 8.38M | 8.05M | 5.69M | 8.14M | 4.91M | 3.86M | 3.36M | 8.50M | 5.30M | 6.56M | 8.30M | 7.20M | 6.40M | 6.10M | 3.40M | 3.70M | 2.90M | 2.00M | 1.50M | 1.50M | 1.30M | 1.40M | 1.40M | 1.90M | 2.00M |
| Interest Income | 1.08M | 104.00K | 2.32K | 33.92K | 71.35K | 45.97K | 19.44K | 12.53K | 17.62K | 8.60K | 125.00 | 3.46K | 2.52K | 4.88K | 20.81K | 37.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 104.00K | 322.00 | 0.00 | 0.00 | 0.00 | 500.46K | 519.95K | 451.91K | 1.26M | 1.11M | 7.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 46.00K | 42.00K | 59.86K | 90.16K | 466.31K | 343.73K | 368.51K | 358.63K | 337.81K | 314.45K | 125.00 | 7.23K | 7.98K | 8.36K | 10.61K | 10.67K | 9.89K | 15.07K | 14.71K | 17.00K | 33.08K | 86.47K | 166.50K | 261.80K | 300.00K | 300.00K | 300.00K | 100.00K | 100.00K | 100.00K | -200.00K | -200.00K | -200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 |
| EBITDA | -10.97M | -13.73M | -13.08M | -10.00M | -11.00M | -13.36M | -4.14M | -4.14M | -601.85K | -8.03M | -8.97M | -4.24M | -6.77M | -5.25M | -7.32M | -5.98M | -5.45M | -7.61M | -4.45M | -3.35M | -3.09M | -3.22M | -3.44M | -4.82M | -7.90M | -6.80M | -6.00M | -5.90M | -3.20M | -3.50M | -3.00M | -2.10M | -1.60M | -1.30M | -1.10M | -1.20M | -1.20M | -1.80M | -1.70M |
| EBITDA Ratio | -5,221.43% | -0.56% | -2,552.44% | 0.00% | -4,234.48% | -1,148.71% | -1,569.00% | -1,379.28% | -6.37% | -128.73% | -2,036.14% | -439.47% | -500.18% | -726.46% | 178.05% | -296.14% | -1,065.76% | -1,496.61% | -1,012.10% | -677.10% | -1,263.61% | -7.74% | -203.32% | -327.67% | -7,600.00% | -6,900.00% | -6,600.00% | -6,500.00% | -3,600.00% | -3,700.00% | -3,000.00% | -2,100.00% | -1,600.00% | -1,600.00% | -1,300.00% | -1,300.00% | -1,200.00% | -1,800.00% | -566.67% |
| Operating Income | -11.01M | -13.88M | -13.14M | -9.98M | -11.47M | -14.29M | -6.08M | -4.51M | -944.76K | -5.04M | -7.92M | -4.13M | -5.03M | -5.25M | -7.32M | -5.99M | -5.49M | -7.63M | -4.47M | -3.36M | -3.12M | -3.31M | -3.60M | -5.09M | -8.20M | -7.10M | -6.30M | -6.00M | -3.30M | -3.60M | -2.80M | -1.90M | -1.40M | -1.40M | -1.20M | -1.30M | -1.30M | -1.80M | -1.70M |
| Operating Income Ratio | -5,243.33% | -0.56% | -2,563.06% | 0.00% | -4,588.50% | -1,284.41% | -1,676.02% | -1,503.00% | -10.21% | -137.54% | -2,036.17% | -439.84% | -501.23% | -718.27% | -693.35% | -290.31% | -1,128.14% | -1,499.58% | -1,015.44% | -680.54% | -1,277.15% | -63.79% | -213.17% | -345.46% | -8,200.00% | -7,100.00% | -6,300.00% | -6,000.00% | -3,300.00% | -3,600.00% | -2,800.00% | -1,900.00% | -1,400.00% | -1,400.00% | -1,200.00% | -1,300.00% | -1,300.00% | -1,800.00% | -566.67% |
| Total Other Income/Expenses | 1.08M | 104.00K | 7.69K | -114.16K | 71.35K | 45.97K | 1.07M | -507.42K | -434.28K | -4.56M | -2.16M | -118.24K | -1.75M | 73.09K | -9.17M | 167.91K | 34.15K | 26.72K | 14.51K | 4.33K | 0.00 | -2.82M | 0.00 | 0.00 | -300.00K | 100.00K | 600.00K | 600.00K | 400.00K | 200.00K | 200.00K | 200.00K | 200.00K | 300.00K | 200.00K | 100.00K | 0.00 | 1.80M | 1.70M |
| Income Before Tax | -9.93M | -13.77M | -13.13M | -10.09M | -11.82M | -14.24M | -5.01M | -5.02M | -1.38M | -9.61M | -10.08M | -4.25M | -6.78M | -5.18M | -16.49M | -5.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.13M | 0.00 | 0.00 | -8.50M | -7.00M | -5.70M | -5.40M | -2.90M | -3.40M | -2.60M | -1.70M | -1.20M | -1.10M | -1.00M | -1.20M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -4,728.57% | -0.56% | -2,561.55% | 0.00% | -4,727.46% | -1,280.28% | -1,381.79% | -1,672.14% | -14.90% | -261.94% | -2,592.28% | -452.42% | -675.65% | -708.27% | -1,561.76% | -282.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -118.18% | 0.00% | 0.00% | -8,500.00% | -7,000.00% | -5,700.00% | -5,400.00% | -2,900.00% | -3,400.00% | -2,600.00% | -1,700.00% | -1,200.00% | -1,100.00% | -1,000.00% | -1,200.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -280.00K | -181.29K | 40.15K | 175.80K | 289.95K | 500.46K | 12.53K | 17.62K | 1.26M | 1.11M | 430.00 | 600.00K | -73.09K | 9.17M | -167.91K | 259.65K | -26.72K | -14.51K | -4.33K | -4.67K | -23.51K | -32.28K | -120.98K | 300.00K | 0.00 | -500.00K | -600.00K | -300.00K | -200.00K | 200.00K | 100.00K | 100.00K | -300.00K | -100.00K | 0.00 | 100.00K | 1.80M | 1.70M |
| Net Income | -9.81M | -13.49M | -12.95M | -10.13M | -11.99M | -14.00M | -5.01M | -5.02M | -1.38M | -9.61M | -10.08M | -4.25M | -7.38M | -5.18M | -16.49M | -5.82M | -5.46M | -7.60M | -4.45M | -3.36M | -3.11M | -3.29M | -3.57M | -4.96M | -8.50M | -7.10M | -5.80M | -5.40M | -3.00M | -3.40M | -2.80M | -1.80M | -1.30M | -1.10M | -1.10M | -1.30M | -1.40M | -1.80M | -1.70M |
| Net Income Ratio | -4,671.90% | -0.55% | -2,526.17% | 0.00% | -4,797.78% | -1,258.07% | -1,381.79% | -1,672.14% | -14.90% | -261.94% | -2,592.28% | -452.42% | -735.46% | -708.27% | -1,561.76% | -282.17% | -1,121.12% | -1,494.33% | -1,012.14% | -679.66% | -1,275.24% | -63.34% | -211.26% | -337.24% | -8,500.00% | -7,100.00% | -5,800.00% | -5,400.00% | -3,000.00% | -3,400.00% | -2,800.00% | -1,800.00% | -1,300.00% | -1,100.00% | -1,100.00% | -1,300.00% | -1,400.00% | -1,800.00% | -566.67% |
| EPS | -0.32 | -0.44 | -0.45 | -0.46 | -0.61 | -0.79 | -0.41 | -0.57 | -0.14 | -1.00 | -1.17 | -0.53 | -1.01 | -0.79 | -2.70 | -1.02 | -1.20 | -1.81 | -1.14 | -0.92 | -0.94 | -1.10 | -1.26 | -1.81 | -3.29 | -2.79 | -2.29 | -2.24 | -1.35 | -1.59 | -1.37 | -0.91 | -0.68 | -0.68 | -0.68 | -0.68 | -0.91 | -1.14 | -1.14 |
| EPS Diluted | -0.32 | -0.44 | -0.45 | -0.46 | -0.61 | -0.79 | -0.41 | -0.57 | -0.14 | -1.00 | -1.17 | -0.53 | -1.01 | -0.79 | -2.70 | -1.02 | -1.20 | -1.81 | -1.14 | -0.92 | -0.94 | -1.10 | -1.26 | -1.81 | -3.16 | -2.69 | -2.29 | -2.17 | -1.30 | -1.59 | -1.37 | -0.91 | -0.68 | -0.68 | -0.68 | -0.68 | -0.91 | -1.14 | -1.14 |
| Weighted Avg Shares Out | 30.98M | 30.37M | 28.58M | 22.23M | 19.79M | 17.62M | 12.20M | 8.74M | 9.63M | 9.57M | 8.64M | 7.98M | 7.33M | 6.53M | 6.10M | 5.69M | 4.55M | 4.19M | 3.89M | 3.65M | 3.30M | 2.99M | 2.84M | 2.74M | 2.58M | 2.54M | 2.53M | 2.41M | 2.22M | 2.13M | 2.05M | 1.98M | 1.90M | 1.61M | 1.61M | 1.90M | 1.54M | 1.58M | 1.49M |
| Weighted Avg Shares Out (Dil) | 30.98M | 30.37M | 28.58M | 22.23M | 19.79M | 17.62M | 12.20M | 8.74M | 9.63M | 9.57M | 8.64M | 7.98M | 7.33M | 6.53M | 6.10M | 5.69M | 4.55M | 4.19M | 3.89M | 3.65M | 3.30M | 2.99M | 2.84M | 2.74M | 2.69M | 2.64M | 2.53M | 2.49M | 2.31M | 2.13M | 2.05M | 1.98M | 1.90M | 1.61M | 1.61M | 1.90M | 1.54M | 1.58M | 1.49M |
ANIX Stock Price: Over 15% Increase Pre-Market Explanation
The stock price of Anixa Biosciences Inc (NASDAQ: ANIX) increased by over 15% pre-market. This is why it happened.
Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic
SAN JOSE, Calif., May 26, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that its ovarian cancer vaccine technology is part of an award from...
Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application
SAN JOSE, Calif., May 20, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (US FDA) has provided details...
OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie
HALLE (SAALE), Germany, May 7, 2021 /PRNewswire/ -- OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug discovery technologies and assets, including its drug discovery collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology...
Anixa's Stock Craters As FDA Slaps Clinical Hold On CAR-T Program
Anixa Biosciences Inc (NASDAQ: ANIX) shares drop after the FDA has requested additional information on its Chimeric Antigen Receptor-T cell therapy (CAR-T) being developed in partnership with Moffitt Cancer Center (MCC). The study under the Investigational New Drug (IND) application has been placed on...
Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for CAR-T Therapy
SAN JOSE, Calif., April 19, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (US FDA) has requested additional...
Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic
SAN JOSE, Calif., April 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will...
Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million
SAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that, due to demand, the underwriter has agreed...
Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology
SAN JOSE, Calif., March 12, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European...
Source: https://incomestatements.info
Category: Stock Reports